Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452018 | 1.00 | CYP2A6 (0.54) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL30687563 | 0.87 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL13244061 | 0.87 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL21312051 | 0.87 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL9656595 | 0.87 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL2751114 | 0.87 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL1690651 | 0.87 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL30398823 | 0.87 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL17177981 | 0.83 | CYP11B1 (0.61) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL18682051 | 0.83 | CYP11B1 (0.61) | CYP2A6ALDH1A1CYP1A2CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| CN-117986252-A | O-phenanthroline-containing compound and application thereof | 北京云基科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3044210-A2 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2016-07-20 | — | — | EP | disclosed |
| US-5128335-A | Antibiotics | MERCK & CO., INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0481662-A1 | 2-Heteroarylphenyl-carbapenem antibacterial agents | MERCK & CO. INC. (US) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CYP2A6 1609/4885ALDH1A1 653/4885CYP1A2 2977/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CYP2A6 1609/4885ALDH1A1 653/4885CYP1A2 2977/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | CYP2A6 1609/4885ALDH1A1 653/4885CYP1A2 2977/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | CYP2A6 2173/4885ALDH1A1 3178/4885CYP1A2 4150/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | CYP2A6 1097/4885ALDH1A1 3094/4885CYP1A2 3838/4885 |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | CYP11B1, CYP11B2, CYP21A2 | CYP2A6 45/4885ALDH1A1 1150/4885CYP1A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.